A translational study of "Randomized phase II trial evaluating trastuzumab + capecitabine (HX) or lapatinib + capecitabine (LX) in HER2-positive metastatic breast cancer patients previously treated with trastuzumab and taxanes."

A translational study of "Randomized phase II trial evaluating trastuzumab + capecitabine (HX) or lapatinib + capecitabine (LX) in HER2-positive metastatic breast cancer patients previously treated with trastuzumab and taxanes." - A biomarker study of WJOG6110B: Early switch to Lapatinib versus Trastuzumab beyond Progression (ELTOP) study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006464

Enrollment

110

Registered

2011-10-04

Start date

2011-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2-positive metastatic breast cancer

Interventions

trastuzumab + capecitabine lapatinib + capecitabine

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients who were enrolled in the study of "Randomized phase II trial evaluating trastuzumab + capecitabine (HX) or lapatinib + capecitabine (LX) in HER2-positive metastatic breast cancer patients previously treated with trastuzumab and taxanes."Signed written informed consent

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Searching a biomarker for progression-free survival, response rate and survival time	—

Countries

Japan

Contacts

Public ContactShinichiro Nakamura

West Japan Oncology Group Datacenter

datacenter@wjog.jp06-6633-7400

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

A translational study of &quot;Randomized phase II trial evaluating trastuzumab + capecitabine (HX) or lapatinib + capecitabine (LX) in HER2-positive metastatic breast cancer patients previously treated with trastuzumab and taxanes.&quot;